Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 7/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.45 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 2/20 | 0.38 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.38 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.37 |
| ▸ | CPB1 | P15086 | 1/20 | 0.37 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.37 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8957185 | 1.00 | ITGB3 (0.45) | ITGB3ITGA2BSLC6A5FAAHPIN1 | |
| SCHEMBL8957242 | 0.92 | SLC6A5 (0.48) | ITGB3ITGA2BSLC6A5FAAHPIN1 | |
| SCHEMBL8957248 | 0.92 | SLC6A5 (0.48) | ITGB3ITGA2BSLC6A5FAAHPIN1 | |
| SCHEMBL9664611 | 0.91 | SLC6A5 (0.53) | ITGB3ITGA2BSLC6A5FAAHCPB2 | |
| SCHEMBL9664622 | 0.91 | SLC6A5 (0.53) | ITGB3ITGA2BSLC6A5FAAHCPB2 | |
| SCHEMBL19138207 | 0.90 | SLC6A5 (0.54) | ITGB3ITGA2BSLC6A5FAAHNOD1 | |
| SCHEMBL19138238 | 0.90 | SLC6A5 (0.54) | ITGB3ITGA2BSLC6A5FAAHNOD1 | |
| SCHEMBL9664377 | 0.90 | SLC6A5 (0.54) | ITGB3ITGA2BSLC6A5FAAHNOD1 | |
| SCHEMBL20956613 | 0.90 | SLC6A5 (0.54) | ITGB3ITGA2BSLC6A5FAAHNOD1 | |
| SCHEMBL19138227 | 0.90 | SLC6A5 (0.54) | ITGB3ITGA2BSLC6A5FAAHNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339370-A1 | PERFORMANCE-ENHANCING EXCIPIENTS AND METHODS OF REDUCING VISCOSITY AND INCREASING STABILITY OF BIOLOGIC FORMULATIONS | AVANTOR PERFORMANCE MATERIALS, LLC (US) | 2025-11-06 | — | — | US | disclosed |
| WO-2020111229-A1 | DRUG DELIVERY SYSTEM USING SOLUTION | 国立大学法人京都大学 | 2020-06-04 | — | — | WO | disclosed |
| WO-2009034458-A2 | OXYGEN PERMEABLE POLYMERIC NANOCONTAINERS FOR ENCAPSULATION OF SENSITIVE COMPOUNDS | UNIVERSITÄT BASEL (CH) | 2009-03-19 | — | — | WO | disclosed |
| EP-0536262-A4 | SUBSTITUTED HISTIDINES | SMITHKLINE BEECHAM CORP (US) | 1996-08-14 | — | — | EP | disclosed |
| EP-0561979-A1 | USE OF ANGIOTENSIN II ANTAGONISTS IN THE TREATMENT OF ANGINA PECTORIS | SMITHKLINE BEECHAM PLC (GB) | 1993-09-29 | — | — | EP | disclosed |
| EP-0561905-A1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF MACULAR DEGENERATION | SMITHKLINE BEECHAM PLC (GB) | 1993-09-29 | — | — | EP | disclosed |
| EP-0536262-A1 | SUBSTITUTED HISTIDINES | SMITHKLINE BEECHAM CORPORATION (US) | 1993-04-14 | — | — | EP | disclosed |
| WO-1992000068-A1 | SUBSTITUTED HISTIDINES | SMITHKLINE BEECHAM CORPORATION (US) | 1992-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339370-A1 | PERFORMANCE-ENHANCING EXCIPIENTS AND METHODS OF REDUCING VISCOSITY AND INCREASING STABILITY OF BIOLOGIC FORMULATIONS | AADAT, KYNU, PNISR | ITGB3 3803/4885ITGA2B 3816/4885SLC6A5 3122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.